Investigation Report on China Budesonide Market, 2018-2022

Its annual sales increased from approximately CNY 100 million in 2007 to approximately CNY 1.2 billion in 2017 with the CAGR from 2007 to 2017 up to 27.7%.

Reference: 1806295
Price: $2,200.00
Tax included

General

Publisher:
CRI
Geography Covered
China
Publication Date
2018/6/25
Pages
30
Version:
2018
Charts:
20
Language
  • English
  • Chinese
Format
License

Description
Every year, nearly 300 million people in China, including over 50 million cough patients, get infected with respiratory diseases. It is estimated that the number of asthma patients in China has exceeded 20 million. Inhaled corticosteroids are suitable for the long-term treatment of bronchial asthma and can avoid all kinds of adverse reactions caused by systemic use of corticosteroids. At present, the main inhaled corticosteroids used in clinical practice are Budesonide, Fluticasone and Beclomethasone.
In the 1990s, Budesonide was successfully developed by AstraZeneca to be used for the treatment of non-corticosteroid dependent or corticosteroid-dependent bronchial asthma and chronic obstructive pulmonary disease. In Jun. 1997, Budesonide aerosol was approved by the FDA.
In 1994, China approved the import of Budesonide. In 1995, Astra (Wuxi) Pharmaceutical was approved to manufacture and sell Budesonide in China. Budesonide has been developing rapidly since it entered the Chinese market. Its annual sales increased from approximately CNY 100 million in 2007 to approximately CNY 1.2 billion in 2017 with the CAGR from 2007 to 2017 up to 27.7%. There is a high demand for Budesonide in China. The majority of Budesonide currently sold on the market are manufactured by AstraZeneca, Synmosa Biopharma Corporation, Lunan Better Pharmaceutical Co., Ltd., Orion Pharma and Shanghai Sine Pharmaceutical Laboratories Co., Ltd. In terms of sales, AstraZeneca has the highest market share, accounting for more than 90% of the Chinese market in 2017.
Owing to the aggravating environmental pollution and ageing population, China will see a rising incidence of respiratory diseases from 2018 to 2012, which will lead to an ever-expanding Budesonide market.

Topics Covered
-Development history of Budesonide in China
-Size of Chinese Budesonide market
-Market share of major Budesonide manufacturers in China
-Market share of various dosage forms of Budesonide in China
-Budesonide prices on the Chinese market
-Prospects of Chinese Budesonide Market, 2018-2022

 

Table of Contents
1 Relevant Concepts of Budesonide
1.1 Indications of Budesonide
1.2 Development History of Budesonide in China
1.3 Patent Status and Approval Information of Budesonide in China

2 Sales of Budesonide in China, 2013-2017
2.1 Sales Value of Budesonide
2.1.1 Sales Value of Budesonide in China
2.1.2 Sales Value by Region
2.2 Sales Volume of Budesonide
2.2.1 Sales Volume of Budesonide in China
2.2.2 Sales Volume by Regions
2.3 Sales of Various Dosage Forms of Budesonide in China,2013-2017
2.3.1 Suspensions
2.3.2 Sprays
2.3.3 (Powder) Aerosols
3 Analysis on Major Budesonide Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Budesonide Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 AstraZeneca
3.2.1 Enterprise Profile
3.2.2 Sales of AstraZeneca's Budesonide in China
3.3 Synmosa Biopharma Corporation
3.4 Lunan Better Pharmaceutical Co., Ltd.
3.5 Orion Pharma
3.6 Shanghai Sine Pharmaceutical Laboratories Co., Ltd.
Several Manufacturers’ Budesonide Prices on the Chinese Market, 2017-2018
4.1 AstraZeneca
4.2 Synmosa Biopharma Corporation
4.3 Lunan Better Pharmaceutical Co., Ltd.
4.4 Orion Pharma
4.5 Shanghai Sine Pharmaceutical Laboratories Co., Ltd.

5 Prospects of Chinese Budesonide Market, 2018-2022
5.1 Forecast on Market Size
5.2 Forecast on Market Trend

Selected Charts
Chart Patent Status of Budesonide in China
Chart Governmental Approval of Budesonide in China
Chart Sales of Budesonide in China
Chart Sales Value of Budesonide in China, 2013- 2017
Chart Sales Value of Budesonide in Parts of China, 2013-2017
Chart Sales Volume of Budesonide in China, 2013- 2017
Chart Market Share of Top 5 Budesonide Manufacturers in Sales Value, 2013-2017
Chart Market Share and Sales Value of AstraZeneca's Budesonide in China, 2013-2017
Chart Market Share and Sales Value of Synmosa's Budesonide in China, 2013-2017
Chart Market Share and Sales Value of Lunan Better's Budesonide in China, 2013-2017
Chart Sales Value and Market Share of Budesonide Suspensions in China, 2013-2017
Chart Sales Value and Market Share of Budesonide Sprays in China, 2013-2017
Chart Prices of AstraZeneca's Budesonide in Several Chinese Cities, 2017-2018
Chart Prices of SYNMOSA's Budesonide in Several Chinese Cities, 2017-2018
Chart Prices of Lunan Better's Budesonide in Several Chinese Cities, 2017-2018
Chart Forecast on Sales Value of Budesonide in China, 2018-2012

Scroll